This press release may constitute a public disclosure of inside information by Kepler S.p.A. under Regulation (EU) 596/2014 and Commission Implementing Regulation (EU) 2016/1055.
Biofarma Group completes the acquisition of a controlling stake in EmergoPharm, a Polish developer of dietary supplements and medical devices
The transaction marks the Group’s entry into Central and Eastern Europe and adds a differentiated medical device portfolio and agile development and regulatory capabilities to the Group’s offering
Mereto di Tomba (Udine, Italy), September 28, 2026 – The Biofarma Group – a leading global nutraceuticals and cosmetics CDMO, focused on delivering to clients outstanding service, innovation and manufacturing excellence – announces that it has completed the acquisition (the “Acquisition”) of a controlling stake in EmergoPharm Sp. z o.o. (“EmergoPharm”) from its shareholders.
Founded in 2009 and headquartered in Warsaw, Poland, EmergoPharm develops and supplies finished products in the dietary supplements and medical devices and cosmetics sectors, serving international pharmaceutical companies as well as regional OTC and consumer health brand owners across Europe, America, and North Africa. Combining a broad ready-to-market product portfolio, agile development and regulatory capabilities, EmergoPharm enables its clients to bring differentiated products to market quickly and efficiently. The company has also built a distinctive portfolio of medical device dossiers, with particular strength in ear, nose and throat applications.
The Acquisition represents a further step in the international growth strategy of the Biofarma Group and establishes its presence in Central and Eastern Europe, one of the largest and fastest-growing nutraceutical markets in Europe.
In connection with the Acquisition, the Group drew €29 million under its existing €135 million revolving credit facility, which was previously fully undrawn. The proceeds of the drawing are being applied to finance the Acquisition, as well as capital expenditure and general corporate purposes of the Group.
Following completion, EmergoPharm’s founder and CEO, Mariusz Cięciara, will remain fully involved in the project, continuing to lead the company together with the current management team, and working closely with the Group to execute a shared growth plan.
“The acquisition of EmergoPharm strengthens our presence in Central and Eastern Europe, a region of strategic importance for the Group. EmergoPharm brings an agile development organisation, a differentiated medical device portfolio and long-standing relationships with leading pharmaceutical partners across Europe. Together, we will offer our clients an even broader range of innovative solutions, in continuity with our commitment to service, innovation and excellence.” – Alberto Urli, CEO of Biofarma Group
“Joining the Biofarma Group is a natural next step for EmergoPharm. Biofarma’s scale, scientific expertise and international manufacturing footprint will allow us to accelerate our growth and offer our clients an even broader portfolio, while preserving the agility and customer focus that have defined EmergoPharm since its foundation.” – Mariusz Cięciara, Founder and CEO of EmergoPharm
Biofarma remains strongly focused on strengthening its position as a leading global nutraceutical and cosmetics CDMO, developing innovative solutions and technologies to improve people’s health and well-being in a sustainable way.
Biofarma was advised by EY Parthenon as financial and tax due diligence advisor, WKB and Giovannelli e Associati as legal advisers on the M&A aspects of the transaction. Weil, Gotshal & Manges LLP advised Biofarma on the financing aspects of the transaction. OC&C Strategy Consultants, a global strategy consulting firm, provided commercial due diligence support.
***
Biofarma Group
With over €450 million in revenue and over 1,500 employees, Biofarma Group is a leading global nutraceuticals and cosmetics CDMO, focused on delivering to clients outstanding service, innovation and manufacturing excellence. The Group operates 8 production sites, including 3 in Italy, 2 in France, 2 in the US, and 1 in China, and serves its customers in over 75 countries.
Contacts
Media Relations
Email: [email protected]
***
This press release is not an offer of securities for sale in the United States or in any other jurisdiction.
Neither the content of any website of the Biofarma Group nor any website accessible by hyperlinks on the Biofarma Group’s website is incorporated in, or forms part of, this announcement. The distribution of this announcement into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release may include “forward-looking statements” within the meaning of the securities laws of applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this press release, including, without limitation, those regarding the Biofarma Group’s intentions, beliefs or current expectations concerning, among other things, its strategy, plans, objectives, prospects, growth, goals and targets. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance, and the actual results of operations, financial condition and liquidity of the Biofarma Group, and the development of the industry in which it operates, may differ materially from those expressed or implied by the forward-looking statements contained in this press release. Any forward-looking statements speak only as of the date of this press release. Except as required by applicable law or regulation, the Biofarma Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements.
